In conclusion, our results corroborate the hypothesis that combination ALK and IGF-1R inhibition overcomes primary crizotinib resistance in ALK+ lung cancer cells, but does not necessarily overcome acquired crizotinib resistance. The gene discussed is IGF1R; the disease is lung cancer.